95930 20210902121908.0 doi 10.3390/ijerph17207653 sideral 120409 ART-2020-120409 eng Aguilar Palacio, Isabel Universidad de Zaragoza (orcid)0000-0001-7293-701X New Male Users of Lipid-Lowering Drugs for Primary Prevention of Cardiovascular Disease: The Impact of Treatment Persistence on Morbimortality. A Longitudinal Study 2020 Access copy available to the general public Unrestricted The objective of this study was to analyse persistence to lipid-lowering drug use for primary prevention of cardiovascular disease (CVD) in a new users cohort, to explore all-cause and cardiovascular related morbidity, comorbidity and mortality in this group and, finally, to study the relationship between persistence and morbimortality. We selected subjects who started lipid-lowering treatment for primary prevention of CVD between 1 January 2010 and 31 December 2017 (N = 1424), and classified them as treatment-persistent or -nonpersistent. Bivariate analyses were performed to compare sociodemographic and clinical variables, morbimortality and time to event between groups. The association between morbidities was explored using comorbidity network analysis. The effect of persistence was analysed using logistic regression and Cox survival analyses. Only 38.7% of users were persistent with treatment. Persistent and nonpersistent users had similar sociodemographic and clinical profiles, although differed in age, smoking status, and glycemia. Comorbidity networks revealed that the number of co-occurring diagnoses was higher in nonpersistent than persistent users. Adjusted analyses indicated a protective effect of treatment persistence, especially against major adverse cardiovascular events (MACE), but this effect was not statistically significant. Observational studies are crucial to characterize real-world effectiveness. info:eu-repo/grantAgreement/ES/ISCIII-FIS/PI17-01704 info:eu-repo/semantics/openAccess by http://creativecommons.org/licenses/by/3.0/es/ 3.39 2020 PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH 41 / 176 = 0.233 2020 Q1 T1 ENVIRONMENTAL SCIENCES 118 / 273 = 0.432 2020 Q2 T2 PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH 68 / 203 = 0.335 2020 Q2 T2 0.747 2020 Health, Toxicology and Mutagenesis 2020 Q2 Public Health, Environmental and Occupational Health 2020 Q2 Pollution 2020 Q2 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Rabanaque Hernández, María José Universidad de Zaragoza (orcid)0000-0002-6671-5661 Maldonado, Lina Universidad de Zaragoza (orcid)0000-0003-1647-3462 Chaure, Armando Abad-Díez, José María Universidad de Zaragoza (orcid)0000-0001-9466-3902 León-Latre, Montse Universidad de Zaragoza Casasnovas, José Antonio Universidad de Zaragoza (orcid)0000-0002-9887-2629 Malo, Sara Universidad de Zaragoza (orcid)0000-0002-7194-8275 1007 610 Universidad de Zaragoza Dpto. Medicina, Psiqu. y Derm. Area Medicina 4008 623 Universidad de Zaragoza Dpto. Estruc.Hª Econ.y Eco.Pb. Área Métodos Cuant.Econ.Empres 1011 615 Universidad de Zaragoza Dpto. Microb.Ped.Radio.Sal.Pú. Área Medic.Prevent.Salud Públ. 17, 20 (2020), 7653 [13 pp.] Int. j. environ. res. public health International Journal of Environmental Research and Public Health 1661-7827 1856805 http://zaguan.unizar.es/record/95930/files/texto_completo.pdf Versión publicada 490358 http://zaguan.unizar.es/record/95930/files/texto_completo.jpg?subformat=icon icon Versión publicada oai:zaguan.unizar.es:95930 articulos driver 2021-09-02-10:40:36 ARTICLE